Sincalide

Sincalide
Clinical data
Other names	1-De(5-oxo-L-proline)-2-de-L-glutamine-; 5-L-methioninecaerulein, 3-[[2-[[2-[[2-[[2-[[2-[(2-amino-3-carboxy-propanoyl); amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-; methylsulfanyl-butanoyl]amino]acetyl]amino]-3-; (1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl-; butanoyl]amino]-3-[(1-carbamoyl-2-phenyl-ethyl); carbamoyl]propanoic acid
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of; administration	Intravenous
ATC code	V04CC03 (WHO) ;
Legal status
Legal status	UK: Available on a named-patient basis; US: ℞-only;
Identifiers
	IUPAC name α-aspartyl-O-sulfotyrosylmethionylglycyltryptophylmethionyl-α-aspartylphenylalaninamide;
CAS Number	25126-32-3 ;
PubChem CID	32800;
IUPHAR/BPS	864;
DrugBank	DB09142 ;
ChemSpider	8009168 ;
UNII	M03GIQ7Z6P;
KEGG	D05845 ;
ChEMBL	ChEMBL1121 ;
CompTox Dashboard (EPA)	DTXSID7048617 ;
ECHA InfoCard	100.042.384
Chemical and physical data
Formula	C49H62N10O16S3
Molar mass	1143.27 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N;
	InChI InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1 ; Key:IZTQOLKUZKXIRV-YRVFCXMDSA-N ;
	(what is this?) (verify)

Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.

Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.

Clinical data

Other names	1-De(5-oxo-L-proline)-2-de-L-glutamine- 5-L-methioninecaerulein, 3-[[2-[[2-[[2-[[2-[[2-[(2-amino-3-carboxy-propanoyl) amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4- methylsulfanyl-butanoyl]amino]acetyl]amino]-3- (1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl- butanoyl]amino]-3-[(1-carbamoyl-2-phenyl-ethyl) carbamoyl]propanoic acid
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of administration	Intravenous
ATC code	V04CC03 (WHO)
Legal status
Legal status	UK: Available on a named-patient basis US: ℞-only
Identifiers
IUPAC name α-aspartyl-O-sulfotyrosylmethionylglycyltryptophylmethionyl-α-aspartylphenylalaninamide
CAS Number	25126-32-3^Y
PubChem CID	32800
IUPHAR/BPS	864
DrugBank	DB09142^Y
ChemSpider	8009168^N
UNII	M03GIQ7Z6P
KEGG	D05845^Y
ChEMBL	ChEMBL1121^N
CompTox Dashboard (EPA)	DTXSID7048617
ECHA InfoCard	100.042.384
Chemical and physical data
Formula	C₄₉H₆₂N₁₀O₁₆S₃
Molar mass	1143.27 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N
InChI InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1^N Key:IZTQOLKUZKXIRV-YRVFCXMDSA-N^N
^NY (what is this?) (verify)